Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

NCT07509099 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

316

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy
DRUG: PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy

Sponsor

Ji Dongmei